Back to News
Market Impact: 0.25
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Editas Medicine received regulatory and ethics approval in Australia to start a first-in-human Phase 1/2 trial of EDIT-401, an experimental gene-editing therapy for hyperlipidemia and high LDL cholesterol. The approval enables clinical testing; the article provides no efficacy data or trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
EDIT0.70
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is the Chinese stock market missing the AI rally
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Why is T-Mobile stock tumbling today?